DUBLIN, November 27, 2017 /PRNewswire/ --
The "In Vitro Diagnostics (IVD) Quality Control Market - Global Opportunity Analysis and Industry Forecast (2017-2022)" report has been added to Research and Markets' offering.
Global IVD quality controls market is expected to reach USD 1,065.3 million by 2022, at a CAGR of 3.8% during the forecast period of 2017 to 2022.
The rising need of faster and error free laboratory results, improving laboratory efficiency, and technological advancements in multi-analyte third party IVD quality controls are the major factors that significantly impacted the development in In Vitro Diagnostics Quality Controls Market.
Following a comprehensive research on IVD quality control products and an in-depth analysis of the market scenario, the report carries out an impact analysis of the key industry drivers, restraints, trends, and opportunities listed in the market dynamics segment.
Increasing number of accredited clinical laboratories, growing demand for external quality assessment (EQA) support, and increasing mandates from regulatory & accreditation bodies on the use of quality controls are the key market drivers covered in the report which will support the industry growth during the forecast period.
However, additional costs burden associated with quality controls on laboratories, unfavorable reimbursement scenario for IVD tests, and lack of mandatory regulations for clinical laboratory accreditation in many emerging countries restraining the adoption of these quality control products to some extent.
Key Topics Covered:
2. Research Methodology
3. Executive Summary
4. Market Insights
4.2. Market Dynamics
220.127.116.11. Increasing Number of Accredited Clinical Laboratories
18.104.22.168. Increasing Mandates from Regulatory and Accreditation Bodies on the Use of Quality Controls
22.214.171.124. Growing Demand for External Quality Assessment (EQA) Support
126.96.36.199. Other Drivers
188.8.131.52. Additional Costs Burden Associated with Quality Controls on Laboratories
184.108.40.206. Unfavourable Reimbursement Scenario for IVD Tests
220.127.116.11. Lack of Mandatory Regulations for Clinical Laboratory Accreditation in Many Emerging Countries
18.104.22.168. Other Restraints
22.214.171.124. Increasing Demand for Multi Analyte Quality Controls
4.3. Market Share Analysis, By Key Players
5. IVD Quality Control Market, by Product Type
5.2. Quality Controls
5.2.1. Whole Blood Based Quality Controls
5.2.2. Urine Based Quality Controls
5.2.3. Serum & Plasma Based Quality Controls
5.2.4. Other Quality Controls
5.3. Data Management Software
5.4. External Quality Assessment Services
6. IVD Quality Control Market, by Application
6.3. Molecular Diagnostics
6.4. Clinical Chemistry
6.8. Other Applications
7. IVD Quality Control Market, by End User
7.3. Clinical/Reference Laboratories
7.4. Research and Academic Institutes
8. IVD Quality Control Market, by Manufacturer Type
8.2. IVD-Instrument Manufacturers
8.3. Third Party Quality Control Manufactures
8.3.1. Independent Third-Party Quality Controls
8.3.2. Instrument Specific Third-Party Controls
9. Geographic Analysis
10. Competitive Landscape
11. Company Profiles
- Abbott Laboratories
- Becton, Dickinson And Company (BD)
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- Eurotrol B.V.
- F. Hoffmann -La Roche Ltd.
- Fortress Diagnostics Limited
- Helena Biosciences Europe
- Maine Molecular Quality Controls, Inc.
- Merck KGaA
- Omega Diagnostics Group Plc
- Ortho Clinical Diagnostics
- Randox Laboratories Ltd.
- Seracare Life Sciences Inc.
- Sero As
- Siemens Ag
- Sun Diagnostics, LLC.
- Technopath Clinical Diagnostics
- Thermo Fisher Scientific Inc.
- Zeptometrix Corporation
For more information about this report visit https://www.researchandmarkets.com/research/snz48t/in_vitro
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets